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The ovarian steroid hormone, progesterone, and its nuclear receptor, the progesterone receptor, are implicated in
the progression of breast cancer. Clinical trial data on the effects of hormone replacement therapy underscore the
importance of understanding how progestins influence breast cancer growth. The progesterone receptor regulation
of distinct target genes is mediated by complex interactions between the progesterone receptor and other
regulatory factors that determine the context-dependent transcriptional action of the progesterone receptor. These
interactions often lead to post-translational modifications to the progesterone receptor that can dramatically alter
receptor function, both in the normal mammary gland and in breast cancer. This review highlights the molecular
components that regulate progesterone receptor transcriptional action and describes how a better understanding
of the complex interactions between the progesterone receptor and other regulatory factors may be critical to
enhancing the clinical efficacy of anti-progestins for use in the treatment of breast cancer.
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The mitogenic activity of estrogen is well established,
but an under-studied ovarian steroid hormone, progester-
one, is emerging as a primary mitogen in the breast, con-
tributing significantly to genetic programming required for
mammary stem cell self-renewal, mammary gland develop-
ment, proliferation, and hyperplasia [1]. The effects of pro-
gesterone are triggered after binding of progesterone to its
intracellular receptor, the progesterone receptor (PR). The
PR exists in two primary isoforms, differing structurally by
the inclusion of an N-terminal segment unique to the full-
length isoform, PR-B [2] (Figure 1). This region, termed the
B-upstream segment, is missing from the shorter isoform,
PR-A [3]. The two isoforms are encoded by the same gene
(regulated by distinct but tandem upstream promoters) and
are most often co-expressed [4]. The PR is a member of the
steroid hormone receptor subgroup of ligand-activated
transcription factors within the large nuclear receptor
superfamily, and is an important down-stream effector of
estrogen-receptor (ER) signaling; in most circumstances,
estrogen is required for robust PR expression. PR binding* Correspondence: lange047@umn.edu
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2014to DNA, either directly through progesterone response
elements or indirectly through tethering interactions with
other transcription factors, activates transcriptional
profiles associated with mammary gland proliferation and
breast cancer [5-9]. Additionally, PR binding interactions
with transcriptional co-activators and repressors are critical
to PR transcription factor function [10].
PRs are highly post-translationally modified, primarily
through N-terminal phosphorylation (select phosphorylation
sites most relevant to breast cancer biology are highlighted
in Figure 1), acetylation, SUMOylation, and ubiquitination
[9,11-17]. These receptor modifications dramatically alter
PR function, receptor localization and turnover, and pro-
moter selectivity. The PR can be phosphorylated basally in
the absence of the hormonal ligand, but is potently modi-
fied after ligand treatment, in response to local growth
factors or in a cell cycle-dependent manner [12,13,15-17]
(G. Dressing and C. Lange, unpublished data). Mitogenic
protein kinases - such as CDK2, CK2, and MAPK - have
been shown to phosphorylate PR and subsequently modify
PR action. Therefore, PR can be thought of as a ‘mitogenic
sensor’ in the cell, with PR phosphorylation serving as a
readout of kinase activity. Highly mitogenic environments
like cancer, where kinase activities are frequently high, may
be a situation where PR is persistently phosphorylated inntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Figure 1 Schematic of progesterone receptor structure and select phosphorylation sites. Progesterone receptor (PR) isoforms A and B
differ in their inclusion of an N-terminal upstream segment unique to PR-B. Both isoforms contain an identical DNA binding domain (DBD), hinge
region (H) and hormone binding domain (HBD). Full-length PR-B contains 14 phosphorylation sites; serines 81, 294, 345 and 400 have known links
to PR action and gene expression in breast cancer.
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signals (that is, growth factors) may diminish or replace the
need for ligand, thus activating PRs inappropriately.
In addition to receiving direct inputs from protein
kinases via phosphorylation, PR interacts with and ac-
tivates members of cytoplasmic signaling cascades,
such c-SRC [18,19]. These rapid signaling actions of PR
(previously termed non-genomic actions) are independent
of PR’s DNA-binding transcriptional activity [19]. However,
direct PR interactions with components of kinase cas-
cades and subsequent signaling pathway activation are
highly integrated with PR genomic actions. Indeed, kinases
that modify PR, as well as other growth factor-activated
kinases, have been found in association with DNA-bound
(that is, phosphorylated) PRs that function as part of the
same transcription complexes that regulate PR-target gene
promoters and enhancers [16,20,21]. Increasing know-
ledge about post-translational PR modifications and
PR-modifying binding partners suggests that these events
(such as phosphorylation, SUMOylation, and so on) are
required for context-dependent activation of PR.
Understanding PR action is of great clinical significance
in breast cancer, as evidenced by large-scale clinical trials
conducted more than 10 years ago that demonstrated that
PR actions fuel breast cancer growth. In two independent
trials, women whose hormone-replacement therapy (HRT)
regimens included estrogen and synthetic progesterone
(that is, medroxyprogesterone acetate, norethisterone,
or norgestrel/levonorgestrel) had a higher risk of develop-
ing breast cancer than women whose regimens included
only estrogen and no progestins [22,23]. The results of
these trials remain controversial for several reasons,
including the fact that study participants were well
past the onset of menopause when HRT was initiated.Additionally, although synthetic progestins clearly closely
mimic progesterone in vitro, some synthetic progestins
(medroxyprogesterone acetate) may alter androgen recep-
tor (AR) [24] or glucocorticoid receptor (GR) [25] signaling,
exhibit different half-lives, and are metabolized differently
than natural progesterone, and therefore may be associated
with different breast cancer risks relative to their naturally
occurring counterparts [26,27]. Finally, continuous
dosing of progestins as part of HRT may fail to mimic
cyclical lifetime exposure to natural ligand in vivo.
However, taken together, these landmark clinical studies
implicate PR in human breast cancer development and
progression, a finding that is well-supported by animal
studies [28,29]. It is thus important to fully understand
how activated PRs may contribute to early breast cancer
progression, perhaps by driving the transition from steroid
receptor (SR)-positive tumors with better clinical prog-
noses to more aggressive, poorer outcome SR-negative
and luminal-B-type tumors.
Convincing preclinical and clinical evidence suggests
that progestins increase breast cancer risk in part by driving
the proliferation of early lesions [28,30-35]. Even so, at least
five main sources of confusion remain regarding the role
of PR actions in breast cancer (expanded on in Box 1).
First, PR action is context dependent - that is, PR action
differs in normal versus neoplastic tissue and according to
hormone exposure (for example, in the presence versus
absence of estrogen), as well as organ site (for example,
proliferative in the breast versus inhibitory in the uterus).
Moreover, despite convincing progestin-dependent pro-
liferative responses in murine models [32,36,37], early
reports showed that progesterone was anti-proliferative
or non-proliferative in human cells [38-40]. However,
recent work from the laboratory of C. Brisken [41] has
Hagan and Lange BMC Medicine Page 3 of 92014, 12:32
http://www.biomedcentral.com/1741-7015/12/32shown that progesterone is proliferative in human
breast tissue microstructures isolated from normal hu-
man breast specimens. Interestingly, progesterone-
dependent proliferation and signaling is preserved only
when the tissue architecture remains intact; human tis-
sues (previously dissociated) grown in two- or three-
dimensional cultures did not display this proliferative
phenotype, suggestive of further context-dependent PR
actions. Second, PR isoform-specific activities (PR-A
versus PR-B) overlap but can have very disparate activities
within a given target tissue and at selected gene pro-
moters; however, despite their distinct activities, the two
PR-isoforms are not distinguished clinically. Third, ligand-
independent (that is, growth factor- or kinase-dependent)
activities of PR are poorly understood. Fourth, the dosing
(cyclical versus continuous) and source (natural versus
synthetic) of ligand are likely to be key determinants of
the kinetics of PR action. Fifth, although anti-progestins
showed clinical promise in early clinical trials, their use
was limited by liver toxicities (onapristone; [42]) largely
attributable to cross-reactivity with other nuclear receptors,
such as GR. This review will focus on the molecular deter-
minants of PR’s context-dependent actions and their clin-
ical significance. These PR actions are primarily determined
by the availability of PR-binding partners and direct modifi-
cations to PR that dictate promoter selection.Box 1: Complexities of progesterone receptor actions.
• Tissue-specific effects (breast vs. reproductive tract)
• Actions in normal vs. neoplastic tissues
• Isoform-specific actions (PR-A vs. PR-B)
• Lack of clinical designation between PR isoforms
• Ligand-independent actions
• Timing of hormone delivery (continuous vs. cyclical)
• Source of hormone (synthetic vs. natural progesterone)
• PR actions are both ER-dependent and ER-independent
• Efficacy of early anti-progestins in the clinicPost-translational modifications and molecular
interactions alter promoter selectivity
Mounting evidence suggests that post-translational
modifications of PR are key determinants of promoter
selectivity and, in turn, the spectrum of target genes acti-
vated in response to ligand binding (reviewed in [43,44]).
PR promoter preference is partially dictated by differences
in the recruitment of PR and/or its co-activators or co-
repressors to specific DNA sequences. In microarray
analyses, cells expressing wild-type PR or PRs contain-
ing single point-mutations at specific phosphorylation
or SUMOylation sites exhibit dramatic changes inPR-dependent gene expression, specific to precise
post-translational modifications. For example, recent
analyses from the Lange laboratory revealed that PR
phosphorylation on serine 294 favors the subsequent
deSUMOylation on PR lysine 388 [45], thereby yielding a
hyperactive receptor that regulates a unique gene expres-
sion signature found in high ERBB2-expressiong tumors;
this unique phospho-PR gene expression signature
predicted decreased survival in patients treated with
tamoxifen [9]. By contrast, a separate gene expression
pattern is observed when PR is phosphorylated on Ser81
by CK2, a kinase commonly overexpressed in breast
cancers; this modification is associated with the expression
of gene sets involved in interferon and STAT5 signaling
(discussed in more detail below) [8]. Therefore, in response
to ligand, growth factor-mediated PR phosphorylation
(or phosphorylation-dependent alterations of other post-
translational modifications such as SUMOylation) dictates
the selective expression of specific subsets of target genes
and subsequently their transcriptional programs.
Target gene selectivity is achieved not only through
differential recruitment of PR [8,16], but also through asso-
ciated transcriptional co-activators and repressors that are
critical to PR function [9,10,46]. For example, pioneer fac-
tors are specialized subsets of transcription factors that
open defined regions of chromatin, making it accessible for
other transcription factors, like SRs (reviewed in [47,48]).
These types of factors have been identified for other nuclear
receptors, such as ER and AR; however, they have yet to be
identified for PR. Preliminary data suggest that FOXA1 and
STAT5 may be putative pioneer factors for PR [8,49,50];
differential binding interactions between PR and these fac-
tors provide a mechanism for promoter selectivity, perhaps
based on PR post-translational modifications (that is, via
phosphorylation-specific interactions with pioneer factors).
Emerging evidence suggests that interactions between
members of the SR superfamily is an additional regulatory
step in determining target-gene specificity. Interactions
between ER and AR have been the focus of recent in-
vestigations [51,52]. Recent data from the Lanari group
demonstrate the existence of functional cross-talk between
ER and PR; both receptors are localized together on
regulatory regions of PR-target genes, such as CCND1
and MYC, primarily in response to treatment with pro-
gestins [53]. Moreover, work recently published from our
group suggests a complimentary story whereby ER and PR
cooperate to regulate a subset of ER-target genes in re-
sponse to estrogen, but fully independent of exogenously
added progestin. In this case, PR-B appears to act as a scaf-
folding molecule for increased recruitment of signaling
adaptors and protein kinases that phosphorylate ER
within ER/PR-containing transcription complexes [54].
Taken together, these studies suggest that context-
dependent progesterone/PR action may in part depend
Hagan and Lange BMC Medicine Page 4 of 92014, 12:32
http://www.biomedcentral.com/1741-7015/12/32on the presence of other steroid hormones and their
receptors. Detailed biochemical studies of steroid hormone
receptor cross-talk are needed to provide a framework for
a better understanding of differential hormone actions
in pre- and post-menopausal conditions where endogen-
ous hormone levels dramatically differ, as well as during
breast or prostate cancer treatment with hormone-
ablation therapies where closely related steroid hormone
receptors (PR, GR, AR, ER) may substitute for the blocked
activity of another (ER or AR).
Progesterone receptor phosphorylation by CK2 as a
paradigm for receptor modification and regulation
Recent data from our laboratory characterizing PR
phosphorylation on Ser81 by CK2 exemplifies how the
aforementioned modifications and signaling inputs can
alter PR function. CK2 is a ubiquitously expressed kinase
often up-regulated in many different types of cancer,
including breast [55-57]. We and others have shown
that CK2 phosphorylates PR on Ser81, a site that is ba-
sally phosphorylated; however, Ser81 phosphorylation
levels increase markedly in response to ligand (or when
cells enter S phase in the absence of ligand) [16,58]. PRFigure 2 Molecular determinants of progesterone receptor action. Co
transcriptional co-activators (for example, SRC1) and co-repressors (for exam
Pioneer factors: interactions with predicted PR pioneer factors (for example
PR recruitment and subsequent target-gene transcription. Different pioneer
Post-translational modifications: phosphorylation (P), acetylation (Ac), ubiqu
and lysine residues dictate receptor localization, turnover, subcellular localiz
emerging evidence suggests that interactions between members of the stero
specificity. Scaffolding interactions: PR interaction with proteins acting as scaff
thereby contributing to promoter selection. Cell cycle: phosphorylation on se
formation determine receptor function and recruitment of PR to specific targephosphorylation at Ser81 is associated with a specific
gene expression profile, which is correlated with pathways
altered in breast cancer, including genes implicated in
mammary stem cell maintenance and renewal [8,16].
Additionally, the PR target genes whose expression re-
quire phosphorylation at Ser81 are significantly associ-
ated with interferon/inflammation and STAT-signaling
datasets, a unique observation for SRs that represents
a novel link between steroid hormone action, inflammation,
and cancer [8]. A key target gene regulated by Ser81 phos-
phorylation is STAT5 itself, and notably, JAK/STAT signal-
ing is required for potent activation of PR Ser81-regulated
genes, indicating a feed-forward mechanism for gene
program activation (Figure 2). STAT5 is present, along with
phosphorylated PR, on the regulatory region of WNT1, a
key Ser81 target gene known to be involved in cancer
and stem cell biology. Moreover, an in silico analysis
of a publically available PR whole genome chromatin
immunoprecipitation dataset reveals that there is sig-
nificant enrichment of STAT5 consensus sites within
PR-bound chromatin regions, indicating that STAT5
may function as a pioneer factor for phosphorylated PR
(perhaps specifically when PR Ser81 is phosphorylated).-activators/repressors: interactions between PR and known
ple, NCOR/SMRT) are a key determinant of promoter specificity.
, STAT5, putatively) lead to chromatin remodeling, allowing for efficient
factors would be predicted to determine differential PR recruitment.
itination (Ub), and SUMOylation (Sumo) primarily on N-terminal serine
ation, and promoter selectivity. Steroid receptor (SR) interactions:
id receptor superfamily (such as ER and PR) determine PR target-gene
olds (such as DUSP6) determine receptor post-translational modifications,
lect PR serine residues and cell cycle-dependent protein complex
t genes.
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lation of PR may activate gene expression programs
involved in modulating inflammation related to breast
cancer development and progression, including mammary
stem cell maintenance and self-renewal.
Recent studies have defined a new mechanism by which
CK2 and PR interact. Direct interaction between PR and
DUSP6, a negative regulator of the MAPK pathway, is
required to achieve phosphorylation on PR Ser81 [8]. This
regulation occurs independently of DUSP6 phosphatase ac-
tivity, suggesting that DUSP6 is acting as a scaffold for the
interaction between PR and the kinase that phosphor-
ylates Ser81, CK2. Related to this finding, an inter-
action between DUSP6 and CK2 has previously been
identified [59]. Together, this suggests a model whereby
DUSP6 binding to CK2 brings the kinase (CK2) in close
proximity to its substrate (PR Ser81), allowing for efficient
phosphorylation and subsequent selection of target genes
within a given (that is, inflammatory, pro-growth, survival)
genetic program.
Cumulatively, in this vignette describing one context-
dependent scenario of PR action, there exists cross-talk be-
tween mitogenic kinases (that is, CK2 phosphorylation of
PR Ser81), MAPK pathway components (that is, DUSP6
interaction with PR is required for Ser81 phosphorylation),
phosphorylation-dependent gene regulation (that is, Ser81
phosphorylation is required for PR recruitment to specific
subsets of PR target genes), and putative phosphorylation-
specific interactions with a pioneer factor/co-factor
(that is, JAK/STAT-dependence of PR Ser81-regulated
gene expression). PR phosphorylation by CK2 on Ser81
is an exemplary case study of how the molecular deter-
minants of PR action differentially determine receptor
function in breast cancer models (Figure 2).
Progesterone receptor clinical significance in breast cancer
Luminal breast tumors are characterized by their expres-
sion of ER and PR, both of which are good prognostic
markers for predicted response to endocrine therapies.
Interestingly, analysis of The Cancer Genome Atlas data
for the luminal A/B subtype of breast tumors reveals
that heterozygous loss of the PR locus occurs in 40% of
luminal tumors, while 25% of luminal tumors are also
heterozygous for the ER locus. However, these tumors
are overwhelmingly ER-positive and largely respond well
to ER-targeted therapies [60]. Interestingly, PR and ER copy
number is often correlated in individual tumors; tumors
with altered copy numbers for ER are likely to have changes
in PR copy number. Despite these genomic alterations,
both PR and ER mRNA levels are similar in luminal tumors
that are diploid versus those that have lost an allele at these
loci. Thus, gene copy number may not be a robust measure
of the functional (that is, protein) readout for these steroid
hormone receptors and should be interpreted with caution.Moreover, complex intra- and inter-tumoral heterogeneity
may be reflected in analyses of genomic copy number.
Because PR-positive cells release pro-proliferative factors
(that is, PR target-gene products) that induce paracrine
signaling, a small percentage of PR-positive cells within an
individual tumor could have significant effects on tumor
stem cell maintenance and/or tumor growth and prog-
ression. This is a complex situation that makes PR loci gen-
omic heterozygosity difficult to interpret. Cumulatively,
these data underscore the need to gain a much better un-
derstanding of PR signaling within the clinical context.
HRT clinical trial data (discussed above) suggest an
important role for progestins and PR as drivers (that
is, tumor promoters) of breast cancer cell growth.
Progesterone-dependent expression of secreted paracrine
factors is required for self-renewal of (PR-null) stem cells in
the normal mammary gland [32,37] (see below). PR target
genes include soluble factors known to modify cancer stem
cells (WNT1 and RANKL). However, the role of PR target
genes in the maintenance or expansion of cancer progeni-
tor or stem cells is currently unknown. While a minority
of normal (non-pregnant) breast epithelial cells contain
steroid hormone receptors, the majority of luminal breast
cancers express ER and PR (discussed above); heteroge-
neous cells within the breast may contain both ER and
PR, only ER, or only PR [61]. Interestingly, very few somatic
mutations have been identified in ER [62] or PR. With re-
gard to PR, isolated genetic polymorphisms linked to breast
and reproductive cancers appear to increase levels of PR-B
isoform expression, rather than affect PR transcriptional
activity [63-65]. Additionally, the PR-A promoter is more
frequently methylated (that is, silenced) relative to the PR-B
promoter in advanced endocrine-resistant breast cancers
[66]. These data imply that genetic alteration of PR itself is
usually not sufficient to promote tumorigenesis. Alterna-
tively, we propose that oncogenic mutations that drive sig-
naling pathways provide the context for heightened ER and
PR transcriptional activity. For example, high levels of
kinases, such as CK2, CDKs or MAPKs, may induce
persistent progesterone-independent phosphorylation of
PR-B on serines 81 or 294, respectively, thereby leading
to activation of phospho-isoform-specific transcriptional
programs shown to be significantly altered in luminal breast
cancer [8,9]. Therapeutic strategies that target receptor-
modifying protein kinases (that is, anti-CK2, CDK2 or
MAPK) and/or their transcriptional co-factors (that is,
STATs, AP1, SP1, FOXO1, FOXA1) are likely to be very
successful at treating breast cancer and must remain a
direction of robust exploration within the SR field.
Historically, clinical testing of anti-progestins has been
limited [42,67-70]. The results of a clinical trial released in
1999 showed promise for anti-progestins as front-line
breast cancer endocrine therapy [42]. Although patient ac-
crual in this study was small (19 patients), 67% of patients
Hagan and Lange BMC Medicine Page 6 of 92014, 12:32
http://www.biomedcentral.com/1741-7015/12/32achieved tumor remission when treated with onapristone,
a PR type I antagonist that blocks PR binding to DNA, as
front-line endocrine therapy for locally advanced or primary
breast cancer [42]. Liver function test abnormalities were
seen early in this trial, and for that reason new patient ac-
crual was stopped. These liver-associated effects were likely
due to inhibition of GR, a closely related SR. The clinical effi-
cacy of lonaprisan, a type III PR antagonist that promotes
PR repression through the recruitment of transcriptional co-
repressors (while maintaining DNA binding), was measured
in a phase II study as second-line therapy for PR-positive
breast cancer [70]. The results from this trial were dis-
appointing, and the trial was terminated before full patient
accrual. Although a small percentage (14%) of patients
achieved stable disease, no patients achieved complete or
partial responses. This trial likely failed for a number of
reasons, including lack of patient classification, patients
having previous exposure to endocrine therapies, and
a lack of mechanistic understanding of PR inhibitor
action and isoform specificity. Notably, clinically used
anti-progestins that target the ligand-binding domain of
PR may fail to block ligand-independent actions of PR (dis-
cussed above).
Renewed optimism for the use of anti-progestins to
prevent or inhibit breast cancer growth is provided by
more recent preclinical studies of anti-progestins in murine
mammary tumor models. In a dramatic example, treatment
of nulliparous Brca1/Trp53-deficient mice with mifepris-
tone, a PR antagonist, completely inhibited the formation
of mammary gland tumors normally observed in virgin
mice [71], perhaps via modulation of the stem cell com-
partment [30,32]. Newer, highly selective anti-progestins,
which are currently in development by several pharma-
ceutical companies, may increase the clinical utility of
anti-progestins in breast cancer prevention and treatment
and is an area of renewed research interest. Notably, many
patients that relapse while on tamoxifen therapy retain
expression of PR, underscoring the clinical significance of
considering PRs as potentially acting independently of ER
in the context of breast cancer progression during estrogen
ablation (that is, PR expression is most often used clinically
as a measure of ER function) [72,73]. Based on our current
understanding of ligand-dependent and ligand-independent
(kinase-induced) PR actions, classification of patients based
on gene-expression profiling could better identify the sub-
population of patients that would respond well to se-
lective anti-progestins. In addition, cross-talk between
ER and PR (or AR), and growth-factor signaling path-
ways (discussed above) is a likely confounding compo-
nent of development to endocrine-resistant disease, and
should therefore be considered (for example, via the use
of pathway-specific gene biomarkers) when selecting anti-
progestins as potentially beneficial front-line or second-
line therapy [74-76].As mentioned above (and in Box 1), the clinical signifi-
cance of PR isoforms is likely vastly under-appreciated.
In mammary tissue, PR exists as two primary isoforms,
PR-A and PR-B. Although PR-B is required for mammary
gland development and PR-A for uterine development,
these isoforms are most often co-expressed in the same
tissues, typically at a ratio of 1:1. Single isoform expression
in tissues is rare [77-79]. Interestingly, in pre-neoplastic
lesions and samples from patients with breast cancer, this
balanced A:B ratio is often altered, frequently due to
apparent loss of PR-B [78,80]. Cumulative data from the
Lange laboratory has revealed that this imbalance may be
explained by phosphorylation-dependent turnover of tran-
scriptionally active PR-B receptors relative to more stable
and less active PR-A receptors. PR-B but not PR-A under-
goes extensive cross-talk with mitogenic protein kinases
[8,16,45,81,82]. Thus, PR-B is heavily phosphorylated in
response to ligand or via the action of growth factors, and
although this isoform-specific phosphorylation (on PR-B
Ser294) is linked to high transcriptional activity, it is also
coupled to rapid ubiquitin-dependent turnover of the re-
ceptor; regulated PR-B turnover is tightly linked to tran-
scriptional activity (that is, stable non-degradable mutants
of PR are poor transcriptional activators) [83,84]. Of note,
this phosphorylation event (PR-B Ser294) has been detected
in a subset of human tumors [9]. Therefore, loss of PR-B,
as measured by protein levels in clinical immunohisto-
chemistry tests or western blotting may actually reflect high
PR-B transcriptional activity coupled with rapid protein
turnover; peak PR target-gene expression (mRNA) is coin-
cident with nearly undetectable PR protein in experimental
models [85]. Mouse models (mammary gland) predomin-
antly express PR-A prior to pregnancy. In humans, normal
mammary gland function may rely upon balanced expres-
sion of the two PR isoforms. Unfortunately, current immu-
nohistochemistry clinical testing for PR in breast cancer
samples does not differentiate between PR-A and PR-B iso-
forms. Because an imbalance between the two isoforms ap-
pears to be linked to cancerous phenotypes, clinical isoform
distinction may have great diagnostic potential and should
be considered as part of routine luminal cancer work-up.
Emerging data linking progesterone regulation to the
expansion of the mammary stem cell compartment high-
light the role that PR and progesterone may play in early
events in breast cancer. Recent seminal work in murine
models has shown that progesterone can induce the
rapid expansion of mammary stem cells, a population
of SR-negative (that is, ER- and PR-negative) cells located
in the basal epithelial compartment of the mammary gland
[32,37]. Because these cells are PR negative, this expansion
likely occurs through the production of paracrine fac-
tors secreted by neighboring or nearby PR-positive luminal
epithelial cells. Progesterone-dependent expansion of
the mammary stem cell population is mediated by key
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Brisken and colleagues have shown that progesterone-
dependent control of RANKL expression in human tissues
is dependent on intact breast tissue microstructure, and
have confirmed that RANKL is required for progesterone-
induced proliferation [41]; estrogen is a permissive hor-
mone (for PR expression) in this context. Interestingly,
PR-dependent RANKL expression requires STAT5A [50].
This observation is similar to what has been published for
PR regulation of WNTs [8], highlighting an emerging role
for co-ordinate STAT5/PR regulation of select subsets of
PR-target genes related to proliferation and stem cell self-
renewal (see above). Moreover, a PR-positive subpopula-
tion of mammary gland progenitor cells has been recently
discovered [61], challenging the current dogma that mam-
mary gland precursors are strictly SR-negative. These
exciting findings suggest that this long-lived population of
cells, one that is exquisitely sensitive to mutagenic events,
can expand in response to progesterone in both a paracrine
and autocrine fashion [36]. Notably, these PR-positive
mammary stem cells are devoid of ER protein or mRNA
expression, further underscoring the need for understand-
ing PR action as independent of ER in this context.
Conclusions
Recent clinical and preclinical studies clearly demonstrate
the significance of fully understanding the determinants
of context-dependent PR action. They not only challenge
the current clinical diagnostic paradigm in which PR is only
used as a marker of ER transcriptional activity, but also sup-
port a renewed interest in understanding PR as a driver of
breast tumor progression and thus a potentially very useful
target for improved breast cancer therapy [1,86]. In this re-
view, we have highlighted the concept that gene-expression
analyses linked to PR actions suggest different transcrip-
tional programs are activated in response to specific post-
translational modifications (phosphorylation events) and
protein-protein interactions. Although these unique PR gene
signatures highlight functional differences between modified
PRs and their components, the overlap between these
(predominantly proliferative) programs supports a strong
role for PR in early tumor progression toward more aggres-
sive cancer phenotypes, and in some cases, even highlights a
phospho-PR gene signature associated with poor response
to endocrine treatment [9]. Therefore, gene signatures that
define PR action will likely provide a useful paired diagnostic
for clinically applied selective anti-progestins. We conclude
that PR function is highly dependent on the molecular
context, which is defined by such factors as protein kinase
activity (as a major input to receptor post-translational
modifications), co-factor availability, and the presence of
progesterone and other steroid hormone levels and recep-
tors (Figure 2). Future therapeutic approaches should con-
sider targeting receptor-modifying activities in place of orin conjunction with anti-hormone therapies. With proges-
terone emerging as the primary mitogen in the adult breast
(wherein estrogen is permissive for PR expression), under-
standing PR function and identifying or targeting modifiers
of PR action are of critical importance to advancing the
treatment of breast cancer.
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